国内首篇Nature肝癌原创临床研究：看看空转DSP+Xenium在其中的应用
Merged summary
TL;DR - A Nature phase I study reports promising activity from TGFβ-resistant, GPC3-targeted CAR-T cells in advanced hepatocellular carcinoma. DSP and Xenium spatial profiling linked response and resistance to distinct immune-cell states and signaling pathways.
- Among 36 heavily pretreated patients, ORR was 44.4%, median PFS 4.2 months, and median OS 14.2 months.
- The dnTGFβRII “armour” protected CAR-T cells from TGFβ-mediated suppression, although high TGFβ levels could overcome it.
- Responders showed stronger CCL3/CCL5–CCR5-associated T-cell recruitment and fewer exhaustion markers.
- Non-responders exhibited increased TGFB1 signaling, fewer effector T cells, and more exhausted T cells.
Sources (1)
国内首篇Nature肝癌原创临床研究：看看空转DSP+Xenium在其中的应用
TL;DR - A Nature phase I study reports promising activity from TGFβ-resistant, GPC3-targeted CAR-T cells in advanced hepatocellular carcinoma. DSP and Xenium spatial profiling linked response and resistance to distinct immune-cell states and signaling pathways.
- Among 36 heavily pretreated patients, ORR was 44.4%, median PFS 4.2 months, and median OS 14.2 months.
- The dnTGFβRII “armour” protected CAR-T cells from TGFβ-mediated suppression, although high TGFβ levels could overcome it.
- Responders showed stronger CCL3/CCL5–CCR5-associated T-cell recruitment and fewer exhaustion markers.
- Non-responders exhibited increased TGFB1 signaling, fewer effector T cells, and more exhausted T cells.